<DOC>
	<DOCNO>NCT00896337</DOCNO>
	<brief_summary>The ORION study conduct determine whether Epic™ Nitinol Stent primary stenting iliac atherosclerotic lesion show acceptable performance 9 month .</brief_summary>
	<brief_title>EPIC Nitinol Stent System Treatment Atherosclerotic Lesions Iliac Arteries</brief_title>
	<detailed_description>ORION prospective , single arm , non-randomized , multicenter study . A subject could receive maximum 2 study stent 2 target lesion . A maximum 1 non-target lesion 1 non-target vessel could treat commercially approve treatment index procedure .</detailed_description>
	<criteria>Documented chronic , symptomatic iliac artery atherosclerotic disease ( Rutherford/Becker category 1 , 2 , 3 4 ) Lifestylelimiting claudication rest pain De novo restenotic lesion common and/or external iliac artery Subjects bilateral disease may one target lesion treat per side Two target lesion may treat maximum two stent ( two target lesion treat , lesion must cover maximum one stent ) Length diseased segment ( ) &lt; =13 cm treatment plan 2 overlap Epic™ stent Baseline diameter stenosis &gt; = 50 % ( operator visual assessment ) Reference vessel diameter &gt; = 5 mm &lt; =11 mm At least one sufficient ipsilateral infrapopliteal runoff vessel Origin profunda femoris artery patent Target vessel instent restenosis Acute critical limb ischemia Tissue loss ( Rutherford/Becker category 5 6 ) Any major amputation target limb Any minor amputation target limb last 12 month . If minor amputation occur great 12 month , stump need completely heal . Life expectancy le 24 month due medical comorbid condition ( ) could limit subject 's ability participate trial , limit subject 's compliance followup requirement , impact scientific integrity trial Known hypersensitivity contraindication contrast dye , opinion investigator , adequately premedicated . Intolerance antiplatelet , anticoagulant , thrombolytic medication Platelet count &lt; 150,000 mm3 &gt; 600,000 mm3 Serum creatinine &gt; 2.0 mg/dL Dialysisdependent end stage renal disease Pregnancy Current participation another drug device trial complete primary endpoint may potentially confound result trial Known allergy Nitinol Presence arterial lesion ( exception renal , carotid short , focal SFA lesion ) require intervention within 30 day index procedure Superficial femoral artery occlusion limb supply target vessel Heavily calcify and/or excessively tortuous lesion target vessel determine angiography Target lesion within near aneurysm Persistent , intraluminal thrombus propose target lesion postthrombolytic therapy Perforated vessel evidence extravasation contrast medium Vascular graft , aneurysm postsurgical stenosis target vessel Multiple lesion target vessel unable treat maximum two stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>iliac artery stenosis</keyword>
	<keyword>claudication</keyword>
	<keyword>atherosclerotic iliac disease</keyword>
	<keyword>peripheral vascular disease</keyword>
</DOC>